Paion happy with CeNeS's morphine-6-glucuronide
This article was originally published in Scrip
German biotech company Paion has declared itself satisfied with a meta-analysis of Phase II and III data involving the potential intravenous analgesic product, morphine-6-glucuronide (M6G), which it acquired when it bought the UK firm, CeNeS Pharmaceuticals, in June.
You may also be interested in...
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.